Last reviewed · How we verify
NCT04927832: SUDOCU
Detection of Small Fiber Neuropathies by the Non-invasive SUDOSCAN Method During Chronic Autoimmune Pathologies and / or Unexplained Pain Syndromes
NA trial testing SUDOSCAN and EMG (electromyogram) in Systemic Autoimmune Pathologies in 139 participants. Completed in 23 February 2023.
23 February 2023
Quick facts
| Lead sponsor | Hôpital Européen Marseille |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 139 |
| Start date | 6 July 2017 |
| Primary completion | 23 February 2023 |
| Estimated completion | 23 February 2023 |
| Sites | 1 location across France |
Drugs / interventions tested
- SUDOSCAN and EMG (electromyogram)
Conditions studied
- Systemic Autoimmune Pathologies — all drugs for Systemic Autoimmune Pathologies →
- Unexplained Pain Syndrome — all drugs for Unexplained Pain Syndrome →
Sponsor
Hôpital Européen Marseille
Who can join
18 and older, any sex, with Systemic Autoimmune Pathologies or Unexplained Pain Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Very few studies have evaluated the prevalence of small fiber neuropathy (SFN) during pathologies that may be responsible for small fibers damage. SUDOSCAN is a new rapid (2 minutes), automated, reproducible and non-invasive technology to assess small fiber neuropathy by sweat function. With quantitative and reproducible results, SUDOSCAN allows physicians to early detect and follow-up peripheral neuropathy to monitor disease progression and assess treatment efficacy for a better patient management. SUDOSCAN® could allow the identification of SFN in painful patients apart from another pathology already diagnosed responsible for SFN. The purpose of the study SUDOCU is to assess the prevalence of small fiber neuropathies (SFN) in patients with systemic autoimmune pathologies or unexplained pain syndrome.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04927832
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Hôpital Européen Marseille trials
Trials by the same sponsor.
- NCT07422077 — Impact of ERCS on Perceived Stress in Patients Hospitalized in the Post-resuscitation Rehabilitation Service · NA · recruiting
- NCT07491315 — Is Post-exertional Symptom Exacerbation Specific to Patients With Myalgic Encephalomyelitis / Chronic Fatigue Syndrome? · NA · recruiting
- NCT06623188 — Treatment of Episodic Migraine With AURICular Neuromodulation · NA · recruiting
- NCT06332573 — Impact of Onco-sexology Support on the Quality of Life of Patients Newly Diagnosed for Cancer · NA · recruiting
- NCT05249283 — Self and Body Perception in Otoneurological Disorders: Translation and Validation of Measurement Scales · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04927832 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hôpital Européen Marseille
- Last refreshed: 25 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04927832.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing